title: 1,25-Dihydroxyvitamin D3 and 22-oxa-1,25-dihydroxyvitamin D3 in vivo nuclear receptor binding in developing bone during endochondral and intramembranous ossification.
abstract: Target cells for 3H-labeled 1 alpha, 25(OH)2 vitamin D3 [1,25(OH)2D3, vitamin D] and its analog 3H-labeled 22-oxa-1 alpha, 25(OH)2 vitamin D3 (OCT) have been identified during endochondral and intramembranous ossification in developing, undecalcified, unembedded bone, using thaw-mount autoradiography. Two-day-old neonatal rats were injected with [3H]1,25(OH)2D3 or [3H]OCT; after 2 h leg, spine, and head were frozen and sectioned. In the epiphyseal-metaphyseal region specific nuclear concentrations of [3H]1,25(OH)2D3 and [3H]OCT were observed in identical cell populations, being low in cells of the articular and resting zone, intermediate in the proliferating zone, and highest in hypertrophic chondrocytes and in osteoblasts and precursor cells. In the primary spongiosa intertrabecular spaces there were a large number of cells with nuclear labeling--probably osteoblasts and precursor cells. In contrast, in the secondary spongiosa intertrabecular spaces, apparent blood-forming cells were mostly unlabeled. Osteoblasts along bone spicules and compact bone in long bones, vertebrae, and head also showed strong nuclear labeling, as did cells of the periosteum. These data suggest that 1,25(OH)2D3 and OCT regulate development, differentiation, and activities of chondrocytes and osteoblasts, including differentiation of resting chondrocytes into proliferating and hypertrophic chondrocytes that involve "chondroclastic" enlargement of lacunae and "trans-differentiation" of surviving hypertrophic chondrocytes; differentiation of stroma cells into osteoblasts; and in periosteum and other regions of intramembranous ossification differentiation of precursor cells and osteoblasts. Nuclear receptor binding and their selective and hierarchical distribution during cell differentiation appear to correspond to multiple genomic effects toward growth, regeneration and repair. The findings indicate a physiological significance and therapeutic potential of 1,25(OH)2D3 and in particular of its less hypercalcemic analog OCT.
authors.affiliation: Research Laboratories, Chugai Pharmaceutical Company, Tokyo, Japan.
authors.forename: W E
authors.initials: WE
authors.lastname: Stumpf
authors.forename: N
authors.initials: N
authors.lastname: Koike
authors.forename: N
authors.initials: N
authors.lastname: Hayakawa
authors.forename: K
authors.initials: K
authors.lastname: Tokuda
authors.forename: K
authors.initials: K
authors.lastname: Nishimiya
authors.forename: Y
authors.initials: Y
authors.lastname: Tsuchiya
authors.forename: J
authors.initials: J
authors.lastname: Hirate
authors.forename: A
authors.initials: A
authors.lastname: Okazaki
authors.forename: K
authors.initials: K
authors.lastname: Kumaki
mesh_terms: D000818:Animals; D001345:Autoradiography; D001842:Bone and Bones / Q000378:metabolism*; D002117:Calcitriol / Q000031:analogs & derivatives* / Q000378:metabolism*; D002467:Cell Nucleus / Q000378:metabolism; D008297:Male; D010012:Osteogenesis; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D002117:Calcitriol; C051883:maxacalcitol